keyword
MENU ▼
Read by QxMD icon Read
search

Denosumab

keyword
https://www.readbyqxmd.com/read/29350565/safety-and-efficacy-of-denosumab-in-osteoporotic-patients-previously-treated-with-other-medications-a-systematic-review-and-meta-analysis
#1
Andreas Fontalis, Kenanidis Eustathios, Efthymia Prousali, Potoupnis Michael, Tsiridis Eleftherios
Denosumab is a monoclonal antibody that received approval by the FDA for the treatment of osteoporosis in 2010. Available higher level research evidence concerns the treatment of patients that have not received any anti-osteoporotic medication in the past. Further investigation is warranted, since clinicians often face the challenge of administering the most efficacious drug in patients, pretreated with other medications. Areas Covered: We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of denosumab compared to other active anti-osteoporotic agents in patients formerly receiving other treatments...
January 19, 2018: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29344330/developments-in-rare-bone-diseases-and-mineral-disorders
#2
REVIEW
Siobhan Bacon, Rachel Crowley
In the last decade, there have been a number of significant advances made in the field of rare bone diseases. In this review, we discuss the expansion of the classification system for osteogenesis imperfecta (OI) and the resultant increase in therapeutic options available for management of OI. Bisphosphonates remain the most widely used intervention for OI, although the effect on fracture rate reduction is equivocal. We review the other therapies showing promising results, including denosumab, teriparatide, sclerostin, transforming growth factor β inhibition and gene targeted approaches...
January 2018: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/29341831/role-of-bone-modifying-agents-in-multiple-myeloma-american-society-of-clinical-oncology-clinical-practice-guideline-update
#3
Kenneth Anderson, Nofisat Ismaila, Patrick J Flynn, Susan Halabi, Sundar Jagannath, Mohammed S Ogaily, Jim Omel, Noopur Raje, G David Roodman, Gary C Yee, Robert A Kyle
Purpose To update guideline recommendations on the role of bone-modifying agents in multiple myeloma. Methods An update panel conducted a targeted systematic literature review by searching PubMed and the Cochrane Library for randomized controlled trials, systematic reviews, meta-analyses, clinical practice guidelines, and observational studies. Results Thirty-five relevant studies were identified, and updated evidence supports the current recommendations. Recommendations For patients with active symptomatic multiple myeloma that requires systemic therapy with or without evidence of lytic destruction of bone or compression fracture of the spine from osteopenia on plain radiograph(s) or other imaging studies, intravenous administration of pamidronate 90 mg over at least 2 hours or zoledronic acid 4 mg over at least 15 minutes every 3 to 4 weeks is recommended...
January 17, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29340971/denosumab-or-oral-bisphosphonates-in-primary-osteoporosis-a-real-life-study
#4
E Cairoli, S Palmieri, G Goggi, L Roggero, M Arosio, I Chiodini, C Eller-Vainicher
PURPOSE: To compare the response to denosumab (DMAb) therapy with that of oral bisphosphonate (BISPH) treatment in postmenopausal women with primary osteoporosis (PO). METHODS: In this retrospective study, we compared data of 75 PO female patients treated for 24 months with DMab (DMAb Group, age 72.6 ± 8.9 years) with those of 75 PO patients treated with oral bisphosphonates (BISPH Group), matched for age, body mass index, femoral bone mineral density (BMD), prevalent fragility fractures and familiar history of hip fracture...
January 16, 2018: Journal of Endocrinological Investigation
https://www.readbyqxmd.com/read/29339529/management-of-endocrine-disease-atypical-femoral-fractures-risks-and-benefits-of-long-term-treatment-of-osteoporosis-with-anti-resorptive-therapy
#5
Robert Adler
Modern osteoporosis treatment began in the mid-1990's with the approval of amino-bisphosphonates, anti-resorptive agents that have been shown to decrease osteoporotic fracture risk by about half. In 2005, the first cases of atypical femoral fractures (AFF), occurring in the shaft of the femur, were reported. Since then, more cases have been found, leading to great concern among patients and a dramatic decrease in bisphosphonate prescribing. The pathogenesis and incidence of AFF are reviewed herein. Management and an approach to prevention or early detection of AFF are also provided...
January 16, 2018: European Journal of Endocrinology
https://www.readbyqxmd.com/read/29337457/-pharmacovigilance-update
#6
Françoise Livio
The main pharmacovigilance updates in 2017 are reviewed. Denosumab : rebound-associated multiple vertebral fractures after discontinuation. Canagliflozine: increased risk of foot/leg amputations. Biologic and targeted cancer therapies, direct-acting antivirals for chronic hepatitis C: risk of hepatitis B reactivation. Checkpoint inhibitors : immune-related adverse events and graft rejection. Fingolimod : rebound-associated reactivation of MS following withdrawal. Daclizumab: risk of severe liver injury leading to restricted use in MS patients...
January 10, 2018: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29337454/-osteoporosis
#7
Brigitte Uebelhart, Serge Ferrari
The risk for a second fracture within two years after a first one is high. Ten years denosumab treatment show favorable results with a risk of early vertebral fractures in patients with prevalent vertebral fractures when treatment is stopped. Teriparatide is more effective than risedronate to prevent vertebral and clinical fractures in high risk patients. Romosozumab acts as an anabolic agent in osteoporosis. Atypical femoral fractures associated with bisphosphonate treatment could be more frequent in patients with particular anatomical features...
January 10, 2018: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29317292/effects-and-management-of-denosumab-discontinuation
#8
EDITORIAL
Roland Chapurlat
No abstract text is available yet for this article.
January 6, 2018: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/29316026/treatment-dynamics-of-bone-targeting-agents-among-men-with-bone-metastases-from-prostate-cancer-in-the-united-states
#9
Anne M Butler, Karynsa Cetin, Rohini K Hernandez, B Diane Reams, Robert A Overman, Jung I Kim, Bradford R Hirsch, Amy P Abernethy, Alexander Liede, M Alan Brookhart
PURPOSE: To examine the dynamics of treatment with 2 bone-targeting agents (BTAs)-denosumab and zoledronic acid-among men with bone metastases from prostate cancer. METHODS: Using electronic health record data from oncology practices across the US, we identified prostate cancer patients diagnosed with bone metastasis in 2012/2013 without evidence of BTA use within 6 months prior to diagnosis. We examined the risk and predictors of BTA initiation, interruption, and re-initiation...
January 7, 2018: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/29309589/changes-of-circulating-micro-rnas-in-response-to-treatment-with-teriparatide-or-denosumab-in-postmenopausal-osteoporosis
#10
Athanasios D Anastasilakis, Polyzois Makras, Maria Pikilidou, Symeon Tournis, Konstantinos Makris, Ilias Bisbinas, Olga Tsave, John G Yovos, Maria P Yavropoulou
Context: Expression of microRNAs (miRs) related to bone metabolism in the serum maybe affected by anti-osteoporotic treatment. Objective: To investigate the effect of two anti-osteoporotic agents with opposite effects on bone metabolism on microRNA expression profile in the serum. Design: Observational, open label, non-randomized clinical trial. Setting: The outpatient clinics for Metabolic Bone Diseases of 424 General Military Hospital, Thessaloniki, Greece...
December 22, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29297602/effect-of-zoledronic-acid-and-denosumab-in-patients-with-low-back-pain-and-modic-change-a-proof-of-principle-trial
#11
Guoqi Cai, Laura L Laslett, Dawn Aitken, Andrew Halliday, Feng Pan, Petr Otahal, Deborah Speden, Tania M Winzenberg, Graeme Jones
The aim of this study was to evaluate the effect of zoledronic acid (ZA) and denosumab on low back pain (LBP) and Modic change (MC) over 6 months. Adults aged ≥40 years with significant LBP for at least 6 months duration and MC (type 1, 2 or mixed) were randomised to receive ZA (5mg/100ml), denosumab (60mg), or placebo. LBP was measured monthly by Visual Analogue Scale (VAS) and the LBP Rating Scale (RS). MC was measured from MRIs of T12-S1 vertebrae at screening and 6 months. 103 participants with moderate/severe LBP (mean VAS=57mm, mean RS=18) and median total MC area 538 mm2 , were enrolled...
January 3, 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29286564/denosumab-treatment-in-aneurysmal-bone-cyst-evaluation-of-nine-cases
#12
Nilgun Kurucu, Canan Akyuz, Fatma Bilge Ergen, Bilgehan Yalcin, Kemal Kosemehmetoglu, Mehmet Ayvaz, Ali Varan, Burca Aydin, Tezer Kutluk
BACKGROUND: Aneurysmal bone cyst (ABC) is a benign bone tumor. Curettage and bone grafting is the common treatment. Here, we retrospectively evaluate nine patients treated with denosumab. PROCEDURE: Nine patients with ABC, mostly pelvic and vertebral, treated with denosumab were analyzed retrospectively. A 70 mg/m2 denosumab dose was used weekly in the first month, and then monthly. Clinical and radiological responses to treatment were evaluated. RESULTS: In all patients, clinical symptoms including pain and limping regressed completely within 3 months...
December 29, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29279435/-drugs-for-osteoporosis
#13
Seiji Fukumoto
Many important results concerning several drugs for osteoporosis have been presented in ASBMR 2017 meeting. Longer use of denosumab for up to 10 years was shown to induce lower risk of fractures. In addition, antiresorptives were shown to be useful after abaloparatide or romosozumab. Now that several important drugs have been already developed for osteoporosis, research and drug development for other musculoskeletal organs than bone are necessary.
2018: Clinical Calcium
https://www.readbyqxmd.com/read/29277763/the-expression-of-matrix-metalloproteinases-in-receptor-activator-of-nuclear-factor-kappa-b-ligand-rankl-expressing-cancer-of-apocrine-origin
#14
Yumi Kambayashi, Taku Fujimura, Sadanori Furudate, Chunbing Lyu, Takanori Hidaka, Aya Kakizaki, Yota Sato, Kayo Tanita, Setsuya Aiba
Primary cutaneous apocrine carcinoma (PCAC) is a rare and highly aggressive tumor entity. Since there is no conventional therapy for advanced PCAC, exploratory treatments are sometimes used. As we previously reported, receptor activator of nuclear factor kappa-B (RANK) ligand (RANKL)/RANK signaling on M2 macrophages promotes the production of chemokines and proinflammatory cytokines to maintain the immunosuppressive tumor environment of extramammary Paget's disease (EMPD). Since EMPD is a skin adenocarcinoma of apocrine gland origin that expresses high levels of RANKL and matrix metalloproteinase (MMP) 7, and EMPD is associated with the presence of RANK+ M2 macrophages, we hypothesized that tumor-associated macrophages (TAMs) in adenocarcinomas such as PCAC might also express RANKL and MMP7...
January 2018: Anticancer Research
https://www.readbyqxmd.com/read/29275525/a-multicenter-case-registry-study-on-medication-related-osteonecrosis-of-the-jaw-in-patients-with-advanced-cancer
#15
Morten Schiodt, Saroj Vadhan-Raj, Mark S Chambers, Ourania Nicolatou-Galitis, Constantinus Politis, Ruxandra Coropciuc, Stefano Fedele, Danielle Jandial, Jeffrey Zhang, Haijun Ma, Deborah P Saunders
PURPOSE: This observational case registry study was designed to describe the natural history of cancer patients with medication-related osteonecrosis of the jaw (ONJ) and evaluate the ONJ resolution rate. METHODS: Adults with a diagnosis of cancer and with a new diagnosis of ONJ were enrolled and evaluated by a dental specialist at baseline and every 3 months for 2 years and then every 6 months for 3 years until death, consent withdrawal, or loss to follow-up...
December 23, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29251033/significant-improvement-of-bone-mineral-density-by-denosumab-without-bisphosphonate-pre-treatment-in-glucocorticoid-induced-osteoporosis
#16
Takako Suzuki, Yukio Nakamura, Hiroyuki Kato
Objective The aim of this study was to evaluate differences in outcomes of denosumab for a year with or without bisphosphonate (BP) pre-treatment in patients with glucocorticoid-induced osteoporosis (GIO). Methods Forty-eight female patients with GIO with low bone mineral density (T score of BMD; less than -3.0SD) were retrospectively enrolled and classified into the following 2 groups: 1) GIO with BP pre-treatment (BP pre-treated group; n = 24) and 2) GIO without BP treatment (BP pre-untreated group; n = 24)...
December 18, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/29241936/teriparatide-and-denosumab-treatment-for-pregnancy-and-lactation-associated-osteoporosis-with-multiple-vertebral-fractures-a-case-study
#17
Akifumi Ijuin, Hiromi Yoshikata, Ryoko Asano, Taku Tsuburai, Ritsuko Kikuchi, Hideya Sakakibara
OBJECTIVE: Pregnancy and lactation-associated osteoporosis (PLO) is a rare disease, which can lead to vertebral fractures in women of reproductive age. No treatment strategy for PLO has been established. Here we report a case of PLO treated with teriparatide followed by denosumab, in which remarkable improvement in bone mineral density (BMD) was achieved. CASE REPORT: A 27-year-old woman experienced severe back pain two weeks after her first delivery. PLO was diagnosed from her low BMD and multiple vertebral compression fractures...
December 2017: Taiwanese Journal of Obstetrics & Gynecology
https://www.readbyqxmd.com/read/29241742/diagnostic-utility-of-histone-h3-3g34-w-g34r-and-g34-v-mutant-specific-antibodies-for-giant-cell-tumors-of-bone
#18
Hidetaka Yamamoto, Takeshi Iwasaki, Yuichi Yamada, Yoshihiro Matsumoto, Hiroshi Otsuka, Masato Yoshimoto, Kenichi Kohashi, Kenichi Taguchi, Ryohei Yokoyama, Yasuharu Nakashima, Yoshinao Oda
Giant cell tumors of bone (GCTBs) are characterized by mononuclear stromal cells and osteoclast-like giant cells; up to 95% have H3F3A gene mutation. The RANKL inhibitor denosumab, when used for the treatment of GCTB, leads to histological changes such as new bone formation and giant cell depletion. Here we assessed the diagnostic utility of immunohistochemical staining with the antibodies against histone H3.3G34 W, G34R and G34 V mutant proteins for GCTB and other histologically similar bone and joint lesions...
December 11, 2017: Human Pathology
https://www.readbyqxmd.com/read/29233703/the-risk-of-osteonecrosis-on-alveolar-healing-after-tooth-extraction-and-systemic-administration-of-antiresorptive-drugs-in-rodents-a-systematic-review
#19
REVIEW
Victor Lousan do Nascimento Poubel, Carolina Amália Barcellos Silva, Luis André Mendonça Mezzomo, Graziela De Luca Canto, Elena Riet Correa Rivero
PURPOSE: There is much concern about the increasing number of patients with medication-related osteonecrosis of the jaw (MRONJ), and many studies have been published in an attempt to understand the pathophysiology of this condition. This study aimed to systematically review the literature on MRONJ arising in rodents under antiresorptive drug therapy after tooth extraction. METHODS: A search of electronic databases, including LILACS, PROQUEST, PubMed, SCOPUS, and the Web of Science...
November 20, 2017: Journal of Cranio-maxillo-facial Surgery
https://www.readbyqxmd.com/read/29232486/an-essential-warning-editorial-on-vertebral-fractures-after-discontinuation-of-denosumab-a-post-hoc-analysis-of-the-randomized-placebo-controlled-freedom-trial-its-extension
#20
Benjamin Leder
Over the past two decades, osteoporosis treatment options have expanded greatly and physicians and patients are now able to choose among several classes of medications and numerous specific drugs. As these options have grown, however, the choice of which medication to prescribe and how to balance the risks and benefits in specific populations and individual patients has become increasingly complex. This complexity, in turn, combined with the proliferation of well-publicized reports of rare but serious side effects, is exacerbating the recent trend of declining rates of osteoporosis treatment...
December 12, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
keyword
keyword
8329
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"